Denali Therapeutics (DNLI) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 28.6% versus a loss of 18.4%. Over five years, DNLI leads with a -57.9% price change compared with -77.6% for RXRX. Denali Therapeutics is the larger company by market cap ($3.06 billion vs $2.29 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | RXRX |
|---|---|---|
| Share price | $19.16 | $4.27 |
| Market cap | $3.06B | $2.29B |
| 1-day change | -0.62% | -7.78% |
| YTD return | +16.05% | +4.40% |
| 1-year return | +28.59% | -18.36% |
| 5-year return | -57.95% | -77.57% |
| EPS (TTM) | $-2.82 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.30 | $7.18 |
| 52-week low | $13.75 | $2.77 |
| Distance from 52-week high | -29.82% | -40.53% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +88.20% | +69.09% |
| Average volume | 1.61M | 20.24M |
| Shares outstanding | 159.85M | 535.34M |
| Employees | 503 | 600 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed RXRX by 46.9 percentage points over the past year.
- The two companies sit in different sectors: Denali Therapeutics in Healthcare and Recursion Pharmaceuticals in Health Care.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Healthcare · Biotechnology · 503 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
DNLI vs RXRX FAQ
Which is bigger, Denali Therapeutics or Recursion Pharmaceuticals?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $3.06B compared with $2.29B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, DNLI or RXRX?
DNLI returned +28.59% over the past 12 months, compared with -18.36% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Recursion Pharmaceuticals in the same industry?
No. Denali Therapeutics is in the Healthcare sector, while Recursion Pharmaceuticals is in Health Care.